Brain tumour clinical trial title

EORTC protocol 26053-22054 (BR14): A randomised controlled trial of temozolomide as adjuvant or concurrent treatment in anaplastic (WHO grade III) glioma

Brain tumour type

Anaplastic astrocytoma, 

Website

england.ukcrn.org.uk/StudyDetail.aspx?StudyID=2065

Description:

Interventional. This trial is comparing radiotherapy alone with radiotherapy and temozolomide for a type of brain tumour called anaplastic glioma. ‘Anaplastic’ means that the cancer cells look less like normal glial cells than other gliomas. Anaplastic cancers often grow more quickly than other cancers. Doctors usually treat brain tumours with surgery and radiotherapy. Some brain tumours also respond well to chemotherapy. But not all of them do. In this trial, some people won’t have temozolomide. Some will have temozolomide during radiotherapy and some will have it after radiotherapy. Some will have it both during and after radiotherapy. Some people with a brain tumour have changes in two chromosomes Open a glossary item called 1p and 19q in the cell. One or both must be normal in everyone taking part in this trial. Doctors call this ‘non 1p/19q deleted anaplastic glioma’. The aims of this trial are to find out If temozolomide during radiotherapy, after radiotherapy or both during and after radiotherapy is better than radiotherapy alone What the side effects are

Date added:

Open/Closed: Open

Trial ends: December 2015

Provider

MRC CTU

Contact details

Cindy Goldstein :
222 Euston Road

London
NW1 2DA
E-mail: mrcctu.br14@ucl.ac.uk
Telephone: 020 7670 4617

Find on Google maps »